Navigation Links
NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113
Date:11/25/2013

MENLO PARK, Calif., Nov. 25, 2013 /PRNewswire/ -- NewGen Therapeutics, Inc. today announced that preclinical data demonstrate a high therapeutic potential for the company's targeted therapeutic candidate for brain cancer, NT-113. Data from in vivo studies of the experimental drug demonstrated potent anticancer activity and improved survival in a mouse intracranial xenograft model implanted with both EGFR (epidermal growth factor)-amplified and EGFRvIII-mutated glioblastoma cell lines.

(Logo: http://photos.prnewswire.com/prnh/20130408/SF90357LOGO)

The findings were presented by scientists from the Brain Tumor Research Center at the University of California, San Francisco (UCSF) as an oral podium presentation entitled "Preclinical evaluation of NT-113, a novel erbB inhibitor optimized for CNS (central nervous system) biodistribution" at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology, on November 24, 2013 in San Francisco, California.

"Given NT-113's robust anti-cancer activity in multiple intracranial human glioblastoma xenograft studies, excellent pharmacokinetics and very high capacity to cross the blood brain barrier, we plan to initially explore this potential targeted medicine for patients with glioblastoma and non-small cell lung cancer with brain metastases," said Harry D. Pedersen, chief executive officer of NewGen Therapeutics. "EGFR alterations drive many solid tumors to grow and spread.  Overexpression and/or mutations of EGFR occur in 40-60% of glioblastoma patients and 40-80% of non-small cell lung cancer patients, most of whom eventually develop brain metastases. Focusing on patients with EGFR over-expression or mutations in these studies should result in higher response rates, improved survival and more rapid approval timelines."

Mr. Pedersen commented that NewGen planned to initiate Phase 1 studies with NT-113 in early 2015.

About NewGen
NewGen Therapeutics is a privately held pharmaceutical company developing patient-targeted cancer drugs that are designed to overcome limitations of currently available therapies. The company's pipeline includes multiple programs with novel small molecule drug leads against clinically important targets, each addressed to significant medical needs. NT-113, a potent irreversible pan-erbB inhibitor, is the company's most advanced program and has demonstrated anti-cancer activity in several cancer xenograft studies, including glioblastoma, non-small cell lung, breast and gastric cancers.  For more information, please visit our website at http://www.newgenther.com.


'/>"/>
SOURCE NewGen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the ... company will release its fourth quarter and full year ... February 28, 2017. The press release will be followed ... will be open to the public via telephone and ... its financial results and provide a business update. ...
(Date:2/21/2017)... , Feb. 21, 2017 ... announced a new imaging solution that connects Lexmark multifunction ... one of the world,s leading scanning and indexing software ... Connector enables hospitals to use a Lexmark MFP at ... the Solarity workflow, helping facilities reach HIMSS Stage ...
(Date:2/21/2017)... 2017 EMS Find, Inc. (OTCQB: EMSF), ... platforms with focus on e-commerce, health care and ... a worldwide, on-revocable and renewable Software Licensing and ... company serving healthcare organizations and facilities throughout ... EpicMD,s platform eliminates the need for health ...
Breaking Medicine Technology:
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... Doctors ... , CA, directed by Dr. Kendell Mendonca , to its growing network of ... compensation injuries including injuries stemming from car accidents such as whiplash, back pain, neck ...
(Date:2/21/2017)... ... , ... Ray Insurance Agencies, a Dallas area firm providing asset protection services ... a six month charity event aimed at raising local support and donations that will ... the deadliest diseases in America; more than 7.5 million people die from cancer related ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the further expansion of its eHealth App xChange™, providing clinical researchers more ... Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical trials ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is the ... care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and Epic. ... have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets providers ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... coffee house-caliber protein espresso drinks, announced its products are now available for purchase ... Coffee Protein Drink Mix has become popular among health-conscious consumers who love coffee ...
Breaking Medicine News(10 mins):